15 ISC NEWS DAY 1 | WEDNESDAY, FEBRUARY 5, 2025 StrokeConference.org #ISC25 “However, risk profiles and incidence in men and women are similar outside of reproductive years, and reported incidence of CVT is growing in men,” Field said, possibly due in part to factors including improved detection with routine vascular neuroimaging and recognition of CVT as a complication in medically complex patients. In addition, she said, genderspecific risk context is critical in forming CVT treatment and prevention strategies. Women of reproductive potential, for example, need to be treated with anticoagulant prophylaxis for future pregnancies if they do not remain on long-term anticoagulation. “We don’t often think about heavy menstrual bleeding as neurologists, but because this may be a complication in women with CVT who are treated with anticoagulation, we need to counsel around this issue and have strategies to mitigate this issue if it arises,” Field said. CVT is a rare condition, accounting for fewer than 1% of all stroke patients — and is considered a disease with a “good” prognosis. About 85% to 90% of survivors will be functionally independent, Field said. But this overlooks the important and under-studied impact of “invisible” deficits, such headache, mood, fatigue and cognitive issues, as well as other serious complications not wellcaptured by traditional functional outcomes scales, including epilepsy and visual impairment. Wednesday’s session also will feature Seemant Chaturvedi, MD, FAHA, professor of neurology at the University of Maryland School of Medicine in Baltimore. His presentation, “New Insights Regarding Carotid Stenosis Evaluation and Treatment in Women,” will review the reduced benefit of carotid surgery in women and the physiologic basis for this finding. He will also discuss the underrepresentation of women in previous carotid trials. “Carotid stenosis is more common in men, so this may explain why men account for 60% to 70% of patients in trials. Some research indicates that women are less accepting of invasive therapies,” Chaturvedi said. “Nevertheless, it is important to understand the pros and cons of carotid surgery in women, since if there is reduced benefit with surgery, then intensive medical therapy will be preferred.” Women respond differently to treatments such as thrombolysis, carotid surgery and blood pressurelowering medicines, he said. Another important issue is how to address undertreatment of risk factors in women, such as lower statin use and lower rates of anticoagulation for atrial fibrillation. Chaturvedi also reminds clinicians that it’s important to address why stroke outcomes are worse in women. “Is it due to age, social isolation, frailty, or a combination of these factors?” he asked. “Poststroke outcomes such as depression, loneliness and cognitive dysfunction appear to be more common in women. Rehab strategies should be cognizant of these disparities.” Field said Wednesday’s session aligns with De Rango’s body of work and legacy. De Rango died in 2016, shortening an illustrious career dedicated to advancing knowledge of gender differences in stroke and improving stroke treatment for all. “I did not have the opportunity to meet De Rango, but reading about her legacy, I have learned that she was a vascular surgeon who was a leader in her field, an outstanding clinician, a rigorous and ethical researcher, and a dedicated team player,” Field said. “In her roles as a vascular surgeon and frequent research collaborator, I think De Rango’s legacy is recognized by the efforts that are increasingly taken in our work to build bridges internationally to study rare diseases and between specialties to improve communication and accelerate the sharing of ideas and discovery.” PAOLA DE RANGO continued from page 5 Download the official #ISC25 Mobile Meeting Guide App Access to session details, posters, speakers and more are available from any device. Scan the QR code to download to any device. Chaturvedi Call for science: ISC 2026, Nursing Symposium 2026 and HEADS-UP 2026 Session ideas Suggested session submitter opened: Monday, Feb. 3, 2025 Suggested session submitter closes: Monday, March 10, 2025 Abstracts Submission opens: Wednesday, May 28, 2025 Submission closes: Tuesday, Aug. 19, 2025 Late-Breaking Science and Ongoing Clinical Trials Abstracts Submission opens: Wednesday, Oct. 1, 2025 Submission closes: Wednesday, Oct. 29, 2025 The link to submit abstracts and/or session ideas can be found at strokeconference.org on the applicable date above. Start planning now for the International Stroke Conference 2026, Feb. 4-6, in New Orleans, Louisiana. Sponsored by Boston Scientific
RkJQdWJsaXNoZXIy MjI2NjI=